CorMedix Inc. announced that it has appointed Matt David, M.D. as the Company's Executive Vice President and Chief Financial Officer. Dr. David was most recently Head of Strategy at Ovid Therapeutics, a Nasdaq-listed biopharmaceutical company focused on rare neurological diseases. In addition to his recent experience in industry, Dr. David has more than 15 years of experience in finance as a healthcare investment banker and earlier as an equity analyst covering the pharma sector.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.255 USD | +0.29% | -1.96% | +39.76% |
28/05 | CorMedix Shares Rise on Multiyear DefenCath Supply Deal | MT |
28/05 | CorMedix Inc. Announces Commercial Agreement with Top Tier Dialysis Provider | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.76% | 29Cr | |
+14.09% | 926.2Cr | |
-13.94% | 492.25Cr | |
+48.58% | 466.18Cr | |
+14.10% | 427.17Cr | |
+19.75% | 244.09Cr | |
-25.55% | 221.85Cr | |
+18.39% | 214.7Cr | |
-39.57% | 189.23Cr | |
-0.50% | 164.41Cr |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- CorMedix Inc Appoints Matt David as Executive Vice President and Chief Financial Officer